GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totaling 271,752 shares, a decrease of 53.5% from the May 31st total of 584,471 shares. Currently, 7.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,155,944 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Tuesday, April 21st. Finally, Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $150.00.

Hedge Funds Weigh In On GeoVax Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in GeoVax Labs in the 1st quarter valued at approximately $27,000. HRT Financial LP bought a new stake in shares of GeoVax Labs during the fourth quarter worth $31,000. Hudson Bay Capital Management LP acquired a new position in shares of GeoVax Labs during the third quarter worth $47,000. Renaissance Technologies LLC acquired a new position in shares of GeoVax Labs during the fourth quarter worth $104,000. Finally, Armistice Capital LLC acquired a new position in shares of GeoVax Labs during the third quarter worth $253,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Stock Up 0.2%

NASDAQ:GOVX opened at $1.32 on Monday. The stock’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $2.57. The firm has a market capitalization of $4.59 million, a PE ratio of -0.07 and a beta of 3.62. GeoVax Labs has a twelve month low of $0.96 and a twelve month high of $24.50.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Wednesday, April 15th. The company reported $1.85 EPS for the quarter. On average, analysts anticipate that GeoVax Labs will post -8.69 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.